Company: BIVIW
Filing Date: 2025-07-22
Form Type: S-1/A
Source: 0001520138-25-000216
Chunk: 6

Company: BIOVIE INC.
Filing Date: 2025-07-22
Form: S-1/A
Chunk 6
---
 effect a reverse stock split of the outstanding shares of Common Stock, at a ratio
between 1-for-5 and 1-for-10. On June 26, 2025, pursuant to the authority granted by the Company’s stockholders, the Board approved
a reverse stock split of our Common Stock at a ratio of 1-for-10. The Reverse Stock Split became effective at 12:01 a.m. Eastern
Time on July 7, 2025. Other than our historical financial statements and notes thereto included herein, and except where otherwise noted,
all references to our Common Stock presented in this prospectus have been adjusted to give retroactive effect to the Reverse Stock Split.

For investors outside the United States (“U.S.”):
We and the underwriters have not done anything that would permit this offering or the possession or distribution of this prospectus in
any jurisdiction where action for those purposes is required, other than in the U.S. Persons outside the U.S. who come into possession
of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities and the distribution
of this prospectus outside of the U.S.

References to the “Company,” “BioVie,”
“we,” “us,” “our” and similar terms in this prospectus are to BioVie Inc. and its consolidated subsidiaries,
unless the context otherwise requires. This document includes trade names and trademarks of other companies. All such trade names and
trademarks appearing in this document are the property of their respective holders.

<div align='center'>Prospectus Summary</div>

This summary highlights certain information about us and certain information contained elsewhere in this prospectus. This summary is not complete and does not contain all of the information that you should consider before making an investment decision. For a more complete understanding of the Company, you should read and consider carefully the more detailed information included in this prospectus, including the factors described under the heading “Risk Factors,” on page 10 of this prospectus, before making an investment decision.

Overview of the Company

We are a clinical-stage company developing innovative
drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease.

Neurodegenerative Disease Program

The Company acquired the biopharmaceutical assets
of NeurMedix, Inc. (“NeurMedix”) a privately held clinical-stage pharmaceutical company and a related party in June 2021. The
acquired assets included NE3107